Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Ceasing to be a substantial shareholder for IMM (ASX:IMM)

To view the notice, download the attached PDF.

Immutep - Abstracts accepted for Presentation at SITC 2022 (ASX:IMM)

Initial data from INSIGHT-003 trial treating patients with various solid tumours with triple combination therapy of efti, anti-PD-1 therapy, and chemotherapy to be discussed at SITC Im...read more

Immutep - Change of Director's Interest Notice - P Meyers (ASX:IMM)

To view the notice, download the attached PDF.

Immutep - Change of Director's Interest Notice - M Voigt (ASX:IMM)

To view the notice, download the attached PDF.

Immutep - Change of Director's Interest Notice - F Triebel (ASX:IMM)

To view the notice, download the attached PDF.

Immutep - Fast Track granted by US FDA for Efti in 1st line NSCLC (ASX:IMM)

Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1st line non-small cell lung cancer Based on the encouraging Phase II clinical d...read more

Immutep - Application for quotation of securities (ASX:IMM)

For more information, download the attached PDF.

Immutep - Becoming a substantial holder (ASX:IMM)

For more information, download the attached PDF.

Immutep to Participate in Two Upcoming Investor Conferences (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for ca...read more

Immutep Receives A$2.7 million R&D French Tax Incentive (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmun...read more

Immutep - 2022 AGM & Key Dates (ASX:IMM)

SYDNEY, AUSTRALIA – 21 September 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) advises that in accordance with ASX Listing Rule 3.13.1, that it intends to hold its 2022 Annual General ...read more

Immutep - Clinical Development Update for Eftilagimod Alpha (ASX:IMM)

Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung cancer (NSCLC), head & neck squamous cell cancer (HNSCC) and metastatic breast c...read more

Immutep - Initial Director's Interest Notice - Frederic Triebel (ASX:IMM)

To view the notice, download the attached PDF.

Immutep Appoints LAG-3 Pioneer Dr Frederic Triebel to Board (ASX:IMM)

SYDNEY, AUSTRALIA – 13 September 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-rela...read more

Immutep - New investigator-initiated ph2 trial in Soft Tissue Sarcoma (ASX:IMM)

Expansion of the efti clinical development pipeline with a new Phase II setting Efti Phase II trial awarded €1.5M (~A$2.2M) in funding as part of the Polish Medical Research Agency...read more

Viewing: 151 - 165 of 200 Previous | Next